References

Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019.
Illuminating the darkness…PKC inhibitors for metastatic uveal melanoma (Winter Conference on Medicinal & Bioorganic Chemistry 2019)
Lane AM, Kim IK, Gragoudas ES. Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma. JAMA Ophthalmol. 2018;136(9):981-986.
Isakov N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin Cancer Biol. 2018;48:36-52.
Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now?. Ther Adv Med Oncol. 2018;10:1758834018757175.
LXS196, a novel PKC inhibitor for the treatment of uveal melanoma (SCI Symposium on Kinase Inhibitor Design 2018)
Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101(1):38-44.
Garman B, Anastopoulos IN, Krepler C, et al. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Rep. 2017;21(7):1936-1952.
A Phase I Trial of LXS196, a PKC Inhibitor for Uveal Melanoma (Presentation 2017)
Patel SP, Kim DW, Lacey CL, Hwu P. GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report. Medicine (Baltimore). 2016;95(4):e2336.
Johnson DB, Roszik J, Shoushtari AN, et al. Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. Pigment Cell Melanoma Res. 2016;29(4):470-3.
Khoja, L., Atenafu, E. G., & Joshua, A. M. Meta-analysis of phase II trials in metastatic uveal melanoma (MUM) to determine progression-free (PFS) and overall survival (OS) benchmarks for future phase II trials: An irci-ocular melanoma initiative. J Clin Oncol. 2016;34(15_suppl), 9567-9567.
Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846.
Landscape of Genetic Alterations in Uveal Melanoma (ASCO 2014)
Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191-9.
Kategaya L, Perumal S, Hager J, Belmont L. Werner Syndrome Helicase Is Required for the Survival of Cancer Cells with Microsatellite Instability
Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997;278(5340):1064-8.
Hoch NC, Hanzlikova H, Rulten SL, et al. XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia. Nature. 2017;541(7635):87-91.
Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de murcia J, De murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol. 1998;18(6):3563-71.
Sultana R, Abdel-fatah T, Abbotts R, et al. Targeting XRCC1 deficiency in breast cancer for personalized therapy. Cancer Res. 2013;73(5):1621-34.
Gravells P, Grant E, Smith KM, James DI, Bryant HE. Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase. DNA Repair (Amst). 2017;52:81-91.
James DI, Smith KM, Jordan AM, et al. First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib. ACS Chem Biol. 2016;11(11):3179-3190.
Reznik E, Luna A, Aksoy BA, et al. A Landscape of Metabolic Variation across Tumor Types. Cell Syst. 2018;6(3):301-313.e3.
Gutiérrez-vázquez C, Quintana FJ. Regulation of the Immune Response by the Aryl Hydrocarbon Receptor. Immunity. 2018;48(1):19-33.
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.